Literature DB >> 29622944

Intense Focus Yet Many Setbacks for Alzheimer's Disease Drug Development.

Troy Kish.   

Abstract

Despite failures in late-phase trials, the pipeline of medications for Alzheimer's disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.

Entities:  

Year:  2018        PMID： 29622944      PMCID： PMC5871244     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

Review 1.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 2.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Authors:  Reisa A Sperling; Clifford R Jack; Sandra E Black; Matthew P Frosch; Steven M Greenberg; Bradley T Hyman; Philip Scheltens; Maria C Carrillo; William Thies; Martin M Bednar; Ronald S Black; H Robert Brashear; Michael Grundman; Eric R Siemers; Howard H Feldman; Rachel J Schindler
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

Review 3.  Clinical trials of intravenous immunoglobulin for Alzheimer's disease.

Authors:  Norman Relkin
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

4.  AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.

Authors:  Gvido Cebers; Robert C Alexander; Samantha Budd Haeberlein; David Han; Ronald Goldwater; Larry Ereshefsky; Tina Olsson; Naidong Ye; Laura Rosen; Muir Russell; Justine Maltby; Susanna Eketjäll; Alan R Kugler
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.

Authors:  Dev Mehta; Robert Jackson; Gaurav Paul; Jiong Shi; Marwan Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2017-06       Impact factor: 6.206

6.  Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.

Authors:  S P Kennelly; L Abdullah; D Paris; J Parish; V Mathura; M Mullan; F Crawford; B A Lawlor; R A Kenny
Journal:  Int J Geriatr Psychiatry       Date:  2010-10-29       Impact factor: 3.485

Review 7.  BACE1: the beta-secretase enzyme in Alzheimer's disease.

Authors:  Robert Vassar
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Authors:  Susanne Ostrowitzki; Robert A Lasser; Ernest Dorflinger; Philip Scheltens; Frederik Barkhof; Tania Nikolcheva; Elizabeth Ashford; Sylvie Retout; Carsten Hofmann; Paul Delmar; Gregory Klein; Mirjana Andjelkovic; Bruno Dubois; Mercè Boada; Kaj Blennow; Luca Santarelli; Paulo Fontoura
Journal:  Alzheimers Res Ther       Date:  2017-12-08       Impact factor: 6.982
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.